FAS and fatty liver disease: MD001 alleviated fatty liver by reducing TG and FFA levels in db/db mice, which was associated with increased expression levels of ACOX, CPT, and MLYCD and decreased expression levels of ADD1, ACC, and FAS by PPARα activation.